Pfizer beefs up while J&J slims to focus on oncology

Image by PDPics from Pixabay

Both Johnson & Johnson and Pfizer are gearing up to release third-quarter results. While J&J continues to display resilience with its diverse portfolio, Pfizer continues to face challenges with waning demand for its COVID-19 therapies.

To date, Pfizer’s stock is down by roughly a third so far this year, reflecting concerns over its ability to maintain the sky-high revenue levels driven by its COVID-19 portfolio. Also reflecting this trend is moderate volatility in its stock price

J&J, on the other hand, has seen a more modest dip in its stock price so far in 2023 — 8.82% to $162.47. Unlike Pfizer, J&J’s diverse portfolio, spanning consumer health, pharmaceuticals, and medical devices, provides it with a more balanced revenue stream. The company has also been active in addressing challenges, from legal issues to the loss of exclusivity for key drugs li…

Read more
  • 0

New Bayer CEO Bill Anderson’s move to cut management mirrors his Roche playbook

Bill Anderson, who assumed leadership of Bayer in June, is eyeing cuts to the company’s mid- and upper-management. In addition to the cost-savings, Anderson expects the cuts to streamline decision-making. The moves are part of Anderson’s first step in bolder initiative to revamp Bayer’s operational dynamics in the face of investor pressures.

It is relatively rare for an American to lead a major German company. One notable precedent was Bill McDermott at SAP, who made history of the first American CEO of the software company in 2014. At the helm of the software giant, McDermott touted cloud-based evolution, helped introduce the in-memory database platform SAP HANA, prioritized a customer-centric approach, and championed sustainability initiatives.

Anderson, much like McDermott, appears to have bold moves in mind at Bayer. In addition to the cost-savings, he expects these cuts to streamline decision-making. This approach reflects Anderson’s ambi…

Read more
  • 0

Pharma 2023 half-year review reveals winners and losers

[Zerophoto/Adobe Stock]

In many ways, the economic landscape of 2023 has been turbulent. High inflation? Talent shortages? Rising costs of doing business? Volatile currency markets? New regulatory hurdles? Check, check, check. To navigate the choppy waters, a significant number of companies have turned to strategic M&A to drive growth and strengthen product pipelines. Despite these challenges, a handful of pharma companies have managed to thrive, while others have seen steep drops in sales. Here’s an analysis of the leaders and laggards among top Big Pharma pharma companies in the first half of 2023.

The analysis centers on the companies with the highest overall revenue. We looked at companies with the largest percentage change in stock prices from the start of the year to June 27, 2023. ​For context, the NASDAQ Composite Index is up about 30% so far this year.

Pharma 2023 half-year review: Top 5 w…
Read more
  • 0